Conflict of interest: Jens Sønksen is a shareholder in Multicept A/S, Frederiksberg, Denmark.
Original Clinical Article
Penile vibratory stimulation in the treatment of post-prostatectomy incontinence: A randomized pilot study
Article first published online: 27 NOV 2013
© 2013 Wiley Periodicals, Inc.
Neurourology and Urodynamics
How to Cite
Fode, M. and Sønksen, J. (2013), Penile vibratory stimulation in the treatment of post-prostatectomy incontinence: A randomized pilot study. Neurourol. Urodyn.. doi: 10.1002/nau.22536
Robert Pickard led the peer-review process as the Associate Editor responsible for the paper.
Institution at which the work was performed: Department of Urology, Herlev University Hospital, Herlev, Denmark.
- Article first published online: 27 NOV 2013
- Manuscript Accepted: 30 OCT 2013
- Manuscript Received: 17 SEP 2013
- Aase and Ejnar Danielsens Foundation
- conservative treatment;
- nerve stimulation;
- penile vibratory stimulation;
- prostatic neoplasms;
- radical prostatectomy;
- urinary incontinence
To examine penile vibratory stimulation (PVS) in the treatment of post-prostatectomy urinary incontinence (UI).
Patients with post-prostatectomy UI were included in a 12-week trial. A 24-hr pad test and a 72-hr voiding diary were collected at baseline. Participants were randomized to receive PVS for the first 6 weeks (group 1) or for the final 6 weeks (group 2) of the study. The primary outcome was the difference in leakage between groups 1 and 2 at 6 weeks as measured by changes in the pad test. The trial was registered at www.clinicaltrials.org (NCT01540656).
Data from 31 men were available for analyses. The difference in the change on the pad test between the groups did not reach statistical significance at 6 weeks (P = 0.13) while the change in incontinence episodes between groups approached statistical significance (P = 0.052). However, there was a median reduction of −33 g (P = 0.021) on the pad test and a median reduction in daily incontinence episodes of −1 (P = 0.023) in group 1 at 6 weeks. At 12 weeks, group 2 had a median decrease on the pad test of −8 g (P = 0.10) and no change in incontinence episodes. A pooled analysis showed a decline on the pad test of −13.5 g (P = 0.004) after PVS. Small improvements were seen in subjective symptom scores and 58% stated to be satisfied with PVS. Self-limiting side effects were experienced by 15% of patients.
PVS is feasible in the treatment of post-prostatectomy UI. Larger trials are needed to document the clinical efficacy. Neurourol. Urodynam. © 2013 Wiley Periodicals, Inc.